Bone Marrow Transplant Clinical Network

描述（由申请人提供）：宾夕法尼亚大学艾布拉姆森癌症中心（ACC）的骨髓和干细胞移植项目（BMSCTP）是美国最大和最古老的项目之一。这个活跃的项目为所有年龄、性别和种族的患者提供服务，并进行各种形式的干细胞移植，包括自体、异体、非清髓性和脐带血，匹配和不匹配，相关和不相关的无数疾病。Edward Stadtmauer博士是BMT CTN核心临床中心的首席研究员，也是ACC血液恶性肿瘤项目的联合负责人，因此BMT CTN临床试验的患者准入是直接的，这反映在我们中心令人印象深刻的收益中。David Porter博士与Stadtmauer博士密切合作，担任同种异体骨髓移植和免疫治疗主任已有14年。从Penn到BMT CTN累计有210例患者；任何一个中心的第三大收益。宾夕法尼亚大学的研究人员在网络中展示了智力领导力；6个协议小组成员（2个研究主席）和3个委员会主席。宾夕法尼亚大学的研究人员是骨髓瘤系列临床试验取得巨大成功的关键。ACC在所有3个试验中均领先，所有试验均由方案团队领导。宾夕法尼亚大学的BMSCTP一直非常活跃，2009年进行了205例干细胞移植；125例自体，80例异体。BMSCTP是由众多ACC世界一流的研究资源支持：我们的研究方案“他克莫司/MTX联合或不联合MARAVIROC（一种CCR5抑制剂）作为低强度同种异体干细胞移植后GVHD预防的III期试验”在宾夕法尼亚大学的众多备选方案中被选择，以证明我们的专业领域，基于我们自己的试点研究工作，填补了主要的临床需求，即通过降低GVHD来改善同种异体造血干细胞移植的结果，并且可以及时完成。强大的临床研究、患者护理、该领域的思想领袖以及在BMT CTN试验中记录的热情和成功的这些特征，使我们中心在促进有利于血液或骨髓移植的新型治疗方法和策略的有效比较方面具有独特的地位。

DESCRIPTION (provided by applicant): This Bone Marrow and Stem Cell Transplant Program (BMSCTP) of the University of Pennsylvania Abramson Cancer Center (ACC) is among the largest and oldest in the nation. This active program sees patients of all ages, sexes and ethnic origins and conducts all forms of stem cell transplantation including autologous, allogeneic, non-myeloablative and cord blood, matched and mismatched, related and unrelated for a myriad of diseases. Dr. Edward Stadtmauer has been the PI of this BMT CTN Core Clinical Center and is also the Co-leader of the ACC Hematologic Malignancies Program and so access to patients for BMT CTN clinical trials is straightforward and this has been reflected in the impressive accrual from our center. Dr David Porter works very closely with Dr Stadtmauer and has been the Director of Allogeneic Bone Marrow Transplant and Immunotherapy for 14 years. 210 patients have been accrued from Penn to BMT CTN; the 3rd largest accrual of any single center. Penn investigators have demonstrated intellectual leadership in the Network; membership on 6 protocol teams (study chairs for 2) and chair of 3 committees. Penn investigators were key to the highly successful myeloma series of clinical trials. ACC led accrual in all 3 trials with protocol team leadership in all. Penn's BMSCTP remains consistently very active with 205 stem cell transplants conducted in 2009; 125 autologous, 80 allogeneic. The BMSCTP is supported by numerous ACC world- class research resources: Our research proposal, "A PHASE III TRIAL OF TACROLIMUS/MTX WITH OR WITHOUT MARAVIROC (A CCR5 INHIBITOR) AS GVHD PROPHYLAXIS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION" was chosen among many alternatives from Penn to demonstrate an area of our expertise, based on our own pilot study work, fill a major clinical need, namely the improvement of outcome for allogeneic HSCT by reducing GVHD, and can be completed in a timely fashion. These attributes of strong clinical research, patient care, thought leaders in the field and a documented enthusiasm and success in BMT CTN trials uniquely position our Center to promote the efficient comparison of novel treatment methods and strategies to benefit blood or marrow transplantation.